"The voice for cancer physicians and their patients in Massachusetts."

  • Home
  • Resources
  • FDA Approvals
  • FDA approves atezolizumab (Tecentriq) with nab-paclitaxel and carboplatin for metastatic NSCLC without EGFR/ALK aberrations

FDA approves atezolizumab (Tecentriq) with nab-paclitaxel and carboplatin for metastatic NSCLC without EGFR/ALK aberrations

05 Dec 2019 2:14 PM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration approved atezolizumab (Tecentriq; Genentech) in combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. Read full press release

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software